18F-FDG primary tumor uptake to improve N status prediction in cT1 non-metastatic non-small cell lung cancer: development and validation of a positron emission tomography model

被引:0
|
作者
Morland, David [1 ,2 ,3 ,4 ]
Chiappetta, Marco [5 ,6 ]
Falcoz, Pierre-Emmanuel [7 ]
Chenard, Marie-Pierre [8 ]
Annunziata, Salvatore [4 ]
Boldrini, Luca [9 ]
Lococo, Filippo [5 ,6 ]
Imperiale, Alessio [10 ,11 ,12 ]
机构
[1] Inst Godinot, Med Nucl, Reims, France
[2] Univ Reims, EA 3804, CReSTIC, Reims, France
[3] Univ Reims, Lab Biophys, Reims, France
[4] Fdn Policlin Univ A Gemelli IRCCS, Dipartimento Radiol Radioterapia & Ematol, TracerGLab, Unita Med Nucl,GSTeP Radiofarm, Rome, Italy
[5] Univ Cattolica Sacro Cuore, Rome, Italy
[6] Fdn Policlin Univ A Gemelli IRCCS, Chirurgia Torac, Rome, Italy
[7] Hop Univ Strasbourg, Serv Chirurg Thorac, Strasbourg, France
[8] Hop Univ Strasbourg, Serv Pathol, Strasbourg, France
[9] Fdn Policlin Univ A Gemelli IRCCS, Dipartimento Radiol Radioterapia & Ematol, Unita Radioterapia Radiom, Rome, Italy
[10] Inst Cancerol Strasbourg Europe ICANS, Med Nucl, Strasbourg, France
[11] Univ Strasbourg, Hop Univ Strasbourg, Fac Med, Strasbourg, France
[12] Unistra, CNRS, UMR7178, DRHIM,IPHC, Strasbourg, France
关键词
NSCLC; lymph nodes; positron emission tomography; FDG; model; LYMPH-NODE METASTASES; RISK-FACTORS; SCAN;
D O I
10.3389/fmed.2023.1141636
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Occult lymph node involvement is a major issue in the management of non-small cell lung carcinoma (NSCLC), with an estimated prevalence of approximately 2.9-21.6% in 18F-FDG PET/CT series. The aim of the study is to construct a PET model to improve lymph node assessment. Methods: Patients with a non-metastatic cT1 NSCLC were retrospectively included from two centers, one used to constitute the training set, the other for the validation set. The best multivariate model based on Akaike's information criterion was selected, considering age, sex, visual assessment of lymph node (cN0 status), lymph node SUVmax, primary tumor location, tumor size, and tumoral SUVmax (T_SUVmax). A threshold minimizing false pN0 prediction was chosen. This model was then applied to the validation set. Results: In total, 162 patients were included (training set: 44, validation set: 118). A model combining cN0 status and T_SUVmax was selected (AUC 0.907, specificity at threshold: 88.2%). In the validation cohort, this model resulted in an AUC of 0.832 and a specificity of 92.3% versus 65.4% for visual interpretation alone (p=0.02). A total of two false N0 predictions were noted (1 pN1 and 1 pN2). Conclusion: Primary tumor SUVmax improves N status prediction and could allow a better selection of patients who are candidates for minimally invasive approaches.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] 18F-FDG uptake on positron emission tomography in gefitinib-treated non-small cell lung cancer patients
    Na, I.
    Byun, B.
    Kang, H.
    Cheon, G.
    Kim, C.
    Koh, J.
    Choe, D.
    Ryoo, B.
    Lim, S.
    Lee, J.
    Yang, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] 18F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer
    Guan, Jian
    Xiao, Nan J.
    Chen, Min
    Zhou, Wen L.
    Zhang, Yao W.
    Wang, Shuang
    Dai, Yong M.
    Li, Lu
    Zhang, Yue
    Li, Qin Y.
    Li, Xiang Z.
    Yang, Mi
    Wu, Hu B.
    Chen, Long H.
    Liu, Lai Y.
    MEDICINE, 2016, 95 (30)
  • [3] 18F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer
    Guan, Jian
    Chen, Longhua
    Xiao, Nanjie
    Chen, Min
    Zhang, Y.
    Li, Lu
    Yang, Mi
    Li, Qinyang
    Dai, Yongmei
    Zhang, Chi
    Liu, Laiyu
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] Prognostic Value of 18F-FDG Uptake on Positron Emission Tomography in Patients with Pathologic Stage I Non-small Cell Lung Cancer
    Um, Sang-Won
    Kim, Hojoong
    Koh, Won-Jung
    Suh, Gee Young
    Chung, Man Pyo
    Kwon, O. Jung
    Choi, Joon Young
    Han, Joungho
    Lee, Kyung Soo
    Kim, Jhingook
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (11) : 1331 - 1336
  • [5] Correlating circulating tumor cells with 18F-FDG positron emission tomography (PET) uptake in patients with treatment naive non-small cell lung cancer: A pilot study
    Kuhn, Peter
    Keu, Khun Visith
    Nair, Viswam S.
    Luttgen, Maddelyn
    Maestas, Shannon
    Bethel, Kelly
    Souder, Kelly
    Vasanawala, Minal
    Kuschner, Ware
    Iagaru, Andrei H.
    Hoh, Carl
    Nieva, Jorge
    Bazhenova, Lyudmila
    Gambhir, Sanjiv S.
    CANCER RESEARCH, 2012, 72
  • [6] The prediction of response to immunotherapy in non-small cell lung cancer patients by 18F-FDG PET/CT
    Evangelista, Laura
    JOURNAL OF THORACIC DISEASE, 2019, 11 (11) : E221 - E223
  • [7] Impact of Tumor Size and Tracer Uptake Heterogeneity in 18F-FDG PET and CT Non-Small Cell Lung Cancer Tumor Delineation
    Hatt, Mathieu
    Cheze-le Rest, Catherine
    van Baardwijk, Angela
    Lambin, Philippe
    Pradier, Olivier
    Visvikis, Dimitris
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52 (11) : 1690 - 1697
  • [8] Potentials of Non-Invasive 18F-FDG PET/CT in Immunotherapy Prediction for Non-Small Cell Lung Cancer
    Liao, Xuhe
    Liu, Meng
    Wang, Rongfu
    Zhang, Jianhua
    FRONTIERS IN GENETICS, 2022, 12
  • [9] Dual time point 18F-FDG PET/CT of operable non-small cell lung carcinoma: 18F-FDG uptake in the primary tumor in comparison with pathological factors
    Nakagawa, T.
    Matsumoto, J.
    Saito, Y.
    Kambe, T.
    Umehara, I.
    Yoshida, K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S295 - S295
  • [10] [18]fluoromisoniclazole (18F-FMISO) and [18]fluoroclesoxyglucose (18F-FDG) positron emission tomography in non-small cell lung cancer:: volumetric quantification of therapy relevant tumor hypoxia
    Gagel, B.
    Asadpour, B.
    Paulus, T.
    Busch, M.
    Pinkawa, M.
    Piroth, M.
    Holy, R.
    Krohn, T.
    Kaiser, H. J.
    Coenen, H. H.
    Eble, M. J.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2007, 183 : 40 - 40